AbbVie Inc.
250.91USD
+2.1300 (+0.86%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 58.1B | 54.3B | 56.3B | 61.2B | 67.6B | 73.5B |
| Q1 | 13.5B | 12.2B | 12.3B | 13.3B | 15.0B | — |
| Q2 | 14.6B | 13.9B | 14.5B | 15.4B | 17.0B | — |
| Q3 | 14.8B | 13.9B | 14.5B | 15.8B | 17.3B | — |
| Q4 | 15.1B | 14.3B | 15.1B | 16.6B | 18.3B | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 6.63 | 2.72 | 2.39 | 2.36 | 14.01 | 16.28 |
| Q1 | 2.51 | .130 | .770 | .720 | .390 | — |
| Q2 | .510 | 1.14 | .770 | .520 | 2.03 | — |
| Q3 | 2.21 | 1.00 | .880 | .100 | 3.84 | — |
| Q4 | 1.38 |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| .460 |
| -.020 |
| 1.02 |
| 3.87 |
| — |